Adisseo announced its financial results for H1 2024 on Aug. 30. The report indicates that driven by its strong performance in the methionine business segment, Adisseo achieved 7.3 billion yuan in revenue, marking a 15% year-on-year increase. Net profit attributable to shareholders surged to 610 million yuan, showing a remarkable year-on-year growth of 1719%. The gross profit margin remained steady at 31%.

In the second quarter, Adisseo continued its growth momentum from the first quarter. The methionine business experienced a 34% increase in income and an impressive 238% rise in gross profit. Thanks to the successful implementation of the "powder methionine to liquid methionine" business strategy and the efficient coordination of product supply between Chinese and European production platforms, Adisseo achieved a higher global market penetration rate for liquid methionine. The powder methionine business also experienced profit growth due to stable operations and cost competitiveness at the European factory.

Adisseo's specialty products for monogastric animals and aquaculture showed strong sales growth. The high-end organic selenium product, Selisseo?, set its highest monthly sales record in June. Sales revenue for mycotoxin management products increased by 11% year on year and is expected to drive further business growth through close synergy.

Adisseo continued to streamline distribution channels and cut costs by renegotiating outsourced processing costs, boosting digital operations, expanding production capacity, and enhancing synergy. By closely monitoring ESG key indicators and making ongoing investments, Adisseo sustained outstanding safety results, achieving a total recordable incident rate of just 0.11 in the first half of the year.